A share price of Dianthus Therapeutics Inc [DNTH] is currently trading at $24.49, up 1.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNTH shares have gain 6.25% over the last week, with a monthly amount glided 21.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on October 03, 2024, and set its price target to $48. On July 26, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $58 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. H.C. Wainwright initiated its recommendation with a Buy and recommended $40 as its price target on May 16, 2024. Stifel started tracking with a Buy rating for this stock on February 15, 2024, and assigned it a price target of $44. In a note dated December 26, 2023, Jefferies initiated an Buy rating and provided a target price of $22 on this stock.
Dianthus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $18.34 and $33.77. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $24.49 at the most recent close of the market. An investor can expect a potential return of 112.33% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
Trailing Twelve Months sales for Dianthus Therapeutics Inc [NASDAQ:DNTH] were 5.37M which represents 135.06% growth. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -15.45%, Pretax Profit Margin comes in at -12.5%, and Net Profit Margin reading is -12.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.22 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.58 points at the first support level, and at 22.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.43, and for the 2nd resistance point, it is at 26.36.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dianthus Therapeutics Inc [NASDAQ:DNTH] is 18.30. On the other hand, the Quick Ratio is 18.30, and the Cash Ratio is 2.14. Considering the valuation of this stock, the price to sales ratio is 134.99, the price to book ratio is 2.13.
